Market research
CRTX Cortexyme Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 70M
- P/E ratio
- Not available
- Analyst target
- 22.25
- Dividend yield
- 0.0%
- Beta
- 1.4
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 70M
- P/E ratio
- Not available
- Analyst target
- 22.25
- Dividend yield
- 0.0%
- Beta
- 1.4
About
About Cortexyme Inc
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Research context
Cortexyme Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CRTX discussion.
5 years, 6 months ago
Cortexyme, Inc is currently in a long term uptrend where the price is trading 44.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cortexyme, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 66.0% to $-21M since the same quarter in the previous year.
Finally, its free cash flow fell by 21.2% to $-13M since the same quarter in the previous year.
Based on the above factors, Cortexyme, Inc gets an overall score of 2/5.